Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells
Open Access
- 17 March 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0248415
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited treatment options in which the telomere shortening is a strong predictive factor of poor prognosis. Mesenchymal stromal cells (MSC) administration is probed in several experimental induced lung pathologies; however, MSC might stimulate fibrotic processes. A therapy that avoids MSC side effects of transformation would be an alternative to the use of living cells. Membranes particles (MP) are nanovesicles artificially generated from the membranes of MSC containing active enzymes involved in ECM regeneration. We aimed to investigate the anti-fibrotic role of MP derived from MSC in an in vitro model of pulmonary fibrosis. Methods: Epithelial cells (A549) and lung fibroblasts, from IPF patients with different telomere length, were co-cultured with MP and TGF-β for 48h and gene expression of major pro-fibrotic markers were analyzed. Results: About 90% of both types of cells effectively took up MP without cytotoxic effects. MP decreased the expression of profibrotic proteins such as Col1A1, Fibronectin and PAI-1, in A549 cells. In fibroblasts culture, there was a different response in the inhibitory effect of MP on some pro-fibrotic markers when comparing fibroblast from normal telomere length patients (FN) versus short telomere length (FS), but both types showed an inhibition of Col1A1, Tenascin-c, PAI-1 and MMP-1 gene expression after MP treatment. Conclusions: MP conserve some of the properties attributed to the living MSC. This study shows that MP target lung cells, via which they may have a broad anti-fibrotic effect.Keywords
Funding Information
- Ministerie van Economische Zaken
- Instituto de Salud Carlos III (PI18/00367)
- Biomedical National Research Network CIBER
This publication has 55 references indexed in Scilit:
- A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosisJournal of Translational Medicine, 2013
- High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenitaBlood Cells, Molecules, and Diseases, 2012
- Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cellsBMC Pulmonary Medicine, 2012
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant EnvironmentJournal of Proteome Research, 2011
- Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sourcesCellular Immunology, 2010
- Syndromes of Telomere ShorteningAnnual Review of Genomics and Human Genetics, 2009
- Short telomeres are a risk factor for idiopathic pulmonary fibrosisProceedings of the National Academy of Sciences, 2008
- Transforming growth factor-β inhibits telomerase through SMAD3 and E2F transcription factorsCellular Signalling, 2008
- Standardisation of spirometryEuropean Respiratory Journal, 2005